Influenza vaccines: Adenovirus-vectored influenza rapid-and-prolonged-immunologicals-therapeuticals

Influenza vaccines remain a significant area of research within the vaccines industry. Dr De-chu C. Tang, Founder, Vice President and Chief Technology Officer of Vaxin Inc joined us at the World Influenza Congress 2011 to discuss Vaxin's goal to develop an influenza rapid-and-prolonged-immunologicals-therapeuticals (RAPIT) that can be mass-produced at low costs and mass-administered by non-medical personnel; with the capability to …

FDA & EMA viewpoints: regulating adjuvanted #influenza #vaccines

Dr Pieter Neels, Member Committee for Medicinal Products for Human Use at the European Medicines Agency spoke at last year's World Influenza Congress in Vienna on the reasoning behind regulatory standpoints in Europe.   And he did address the elephant in the room before getting started, saying that:   "Regulators cannot do any good: If we are critical: we are …